Page 92 - 2019年10月第30卷第19期
P. 92

·精准医疗·


        ABCB1基因多态性与肾移植患者围手术期服用他克莫司相关不

        良反应的相关性                  Δ


              *
                                     #
        谢培华 ,蔡宜朋,陈泉金,宋洪涛(中国人民解放军联勤保障部队第九ОО医院药学科,福州 350025)
                        +
        中图分类号 R343.1 2;R969.3        文献标志码 A          文章编号 1001-0408(2019)19-2679-06
        DOI  10.6039/j.issn.1001-0408.2019.19.17

        摘  要   目的:探讨腺苷三磷酸(ATP)结合盒转运体B1(ABCB1)基因多态性与肾移植患者围手术期服用他克莫司相关不良反应
        的相关性。方法:选取 2014 年 11 月-2018 年 3 月于我院行肾移植术且术后服用他克莫司的患者 170 例,检测其 ABCB1 C1236T
                                                                            2
       (rs1128503)、ABCB1 G2677T/A(rs2032582)和ABCB1 C3435T(rs1045642)基因型。采用χ 检验比较不同基因型患者间他克莫司相
        关不良反应的发生率,相关不良反应包括消化道反应、肺部感染、肾功能异常、肝功能异常、血糖升高、血脂升高、白细胞降低。采
        用Logistic回归模型进行单位点危险度分析。应用PHASE软件分析患者上述基因的主要单倍型,并分析其主要单倍型与他克莫
        司相关不良反应的相关性。结果:170例患者中,ABCB1 C1236T(rs1128503)检测结果显示CC型21例(占12.3%)、CT型78例(占
        45.9%)、TT型71例(占41.8%);ABCB1 G2677T/A(rs2032582)检测结果显示GG型25例(占14.7%)、GA+GT型95例(占55.9%)、
        AA+AT+TT型50例(占29.4%);ABCB1 C3435T(rs1045642)检测结果显示CC型57例(占33.5%)、CT型82例(占48.2%)、TT型31
        例(占18.3%)。不同ABCB1基因型患者间消化道反应、肺部感染、肾功能异常、血糖升高、血脂升高、白细胞降低的发生率差异均
        无统计学意义(P>0.05),但ABCB1 C1236T(rs1128503)及ABCB1 C3435T(rs1045642)不同基因型患者间肝功能异常的发生率差
        异有统计学意义(P<0.05),ABCB1 G2677T/A(rs2032582)不同基因型患者间肝功能异常的发生率差异虽无统计学意义(P=
        0.069),但 P<0.1。Logistic 回归分析显示,ABCB1 C1236T(rs1128503)CC 型[OR=4.959,95%CI(1.700,14.468),P=0.003]、AB-
        CB1 G2677T/A(rs2032582)GG 型[OR=3.500,95%CI(1.164,10.524),P=0.026]以及 ABCB1 C3435T(rs1045642)CC 型[OR=
        3.033,95%CI(1.012,9.095),P=0.048]均为他克莫司致相关肝功能异常的风险因子。ABCB1 CGC单倍型为主要单倍型,其携带
        与否与他克莫司相关肝功能异常的发生率差异存在统计学意义(P=0.002),且是他克莫司相关肝功能异常的风险因子[OR=
        3.173,95%CI(1.512,6.656),P=0.002]。结论:携带ABCB1 CGC单倍型的肾移植患者围手术期服用他克莫司出现肝功能异常的
        可能性较大。
        关键词 ABCB1基因多态性;他克莫司;不良反应;肝功能异常;肾移植

        Relationship between ABCB1 Gene Polymorphism and Tacrolimus-related ADR in Renal Transplant
        Patients during Perioperative Period
        XIE Peihua,CAI Yipeng,CHEN Quanjin,SONG Hongtao(Dept. of Pharmacy,No. 900 Hospital of the Joint
        Logistics Team,PLA,Fuzhou 350025,China)

        ABSTRACT    OBJECTIVE:To investigate the relationship between ATP-binding cassette subfamily B member 1 (ABCB1)
        polymorphism and tacrolimus-related adverse drug reactions in renal transplant patients during perioperative period. METHODS:
        Totally 170 patients who underwent renal transplantation from Nov. 2014 to Mar. 2018 in our hospital as well as were tested for
        their ABCB1 C1236T(rs1128503),ABCB1 G2677T/A(rs2032582)and ABCB1 C3435T(rs1045642)genotype were selected in
        this study. χ test was used to compare the incidence of tacrolimus-related ADR among patients with different genotypes. The related
                 2
        adverse reactions included digestive tract reaction,pulmonary infection,renal dysfunction,abnormal liver function,elevated blood
        sugar,elevated blood lipid and decreased white blood cells. Logistic regression model was used to analyze the unit point risk. The
        main haplotypes of the above genes were analyzed by PHASE software,and their correlation with tacrolimus-induced ADR was
                                                           analyzed. RESULTS:Among 170 patients,21 cases(12.3%)
           Δ 基金项目:福州总医院院立课题(No.2016L13)
                                                           of CC type,78 cases (45.9%) of CT type and 71 cases
           *药师。研究方向:临床药学。电话:0591-22859783。E-mail:
                                                           (41.8%) of TT type were detected by ABCB1 C1236T
        306398202@qq.com
                                                           (rs1128503). ABCB1 G2677T/A(rs2032582)test showed that
           # 通信作者:主任药师,教授,博士生导师,博士。研究方向:药剂
        学、临床药学、药理学。电话:0591-22859459。E-mail:sohoto@vip.     25 cases (14.7%) were GG type,95 cases (55.9%) were
        163.com                                            GA+GT type and 50 cases(29.4%)were AA+AT+TT type.


        中国药房    2019年第30卷第19期                                             China Pharmacy 2019 Vol. 30 No. 19  ·2679  ·
   87   88   89   90   91   92   93   94   95   96   97